SABCS 2023


Seagen Development Pipeline

Session Info Card

Tucatinib | Breast Cancer | Abstract #1544187

HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer

Tucatinib | Breast Cancer | Abstract #1573051

Trial in progress: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05)

Disitamab Vedotin & Tucatinib | Abstract #1577368

Disitamab vedotin, a clinical stage HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy and in combination with tucatinib in preclinical breast cancer models